Da Ros on the contrary did not find differences in recurrence rate between HER2‐positive ILBC and NST carcinomas, but showed a broader variation in mutational landscape in ILBC than in NST, postulating the more frequent molecular alterations as the leading cause for worse prognosis [8]. The gene discussed is ERBB2; the disease is carcinoma.